Avalo Therapeutics Inc (NQ: AVTX )

13.31 +0.40 (+3.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,851
Open 12.00
Bid (Size) 7.000 (2)
Ask (Size) 14.40 (1)
Prev. Close 12.91
Today's Range 12.00 - 13.31
52wk Range 3.950 - 34.46
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire

Performance

YTD
+52.81%
+52.81%
1 Month
+47.40%
+47.40%
3 Month
+24.63%
+24.63%
6 Month
+22.67%
+22.67%
1 Year
-43.41%
-43.41%

More News

Read More
Avalo Announces Participation in September Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
From Avalo Therapeutics
Via GlobeNewswire
AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.